期刊
CURRENT OPINION IN PHARMACOLOGY
卷 5, 期 4, 页码 350-356出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2005.04.007
关键词
-
Since the discovery that activating mutations of the Ras GTPase were associated with 30% or more of human cancers, the RAF/MEK/ERK pathway has been the focus of intense drug discovery effort. Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise,
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据